SHANGHAI, China, March 1, 2019 – Asieris Pharmaceuticals, a clinical-stage biopharmaceutical company, announced today that Dr. Kevin Pan, the company CEO, will host a CEO Roundtable at 4:00pm on March 6 at the WuXi Healthcare Forum 2019 in Shanghai, China. The Roundtable will commence with an introduction of Asieris, including the company’s R&D strategies, management team, product pipeline, and leading drug candidates currently under global clinical development. based on the interest of the attendees, discussion will cover such hot topics as China-US dual NDA submission, discovery and development of first-in-class oncology drugs, and cross-border partnership.
For more details about the WuXi Healthcare Forum 2019, please visit the website at:
[Archived link no longer working] https://www.wuximediaglobal.com/announcing-latest-agenda-for-wuxi-healthcare-forum-2019/.
About Asieris Pharmaceuticals
Asieris Pharmaceuticals is a science-driven biotech company dedicated to the discovery and development of innovative therapies in oncology, with a China commercial focus on urology and women’s health. Founded in 2010, Asieris currently has operations in Shanghai, Beijing, Taizhou of Jiangsu Province, and the United States.